Nephrotic syndrome complicating alpha-glucosidase replacement therapy for Pompe disease.

Hunley TE, Corzo D, Dudek M, Kishnani P, Amalfitano A, Chen YT, Richards SM, Phillips JA, Fogo AB, Tiller GE
Pediatrics. 2004 114 (4): e532-5

PMID: 15466083 · DOI:10.1542/peds.2003-0988-L

We report a patient with Pompe disease who developed reversible nephrotic syndrome during prolonged, high-dose, experimental, enzyme replacement therapy with recombinant human acid alpha-glucosidase (rhGAA). Because of the development of antibodies to rhGAA and concomitant clinical decline, escalating doses of rhGAA were administered as part of an experimental immune tolerance regimen. Histologic evaluation of kidney tissue revealed glomerular deposition of immune complexes containing rhGAA itself, in a pattern of membranous nephropathy. To our knowledge, this is the first reported case of nephrotic syndrome occurring during enzyme replacement therapy. The nephrotic syndrome gradually resolved after the rhGAA dose was decreased, indicating that decreasing the antigenic load can ameliorate glomerular immune complex deposition associated with enzyme replacement in a highly sensitized patient.

MeSH Terms (9)

alpha-Glucosidases Antibodies Child, Preschool Glycogen Storage Disease Type II Humans Immune Tolerance Kidney Male Nephrotic Syndrome

Connections (4)

This publication is referenced by other Labnodes entities: